Grifols is a global healthcare company whose mission is to improve the health and well being of people worldwide. Based in Barcelona, Spain, the company develops and produces therapies and products in three healthcare divisions: Plasma-derived protein therapies; Hospital products and pharmacy IV solutions; and Diagnostic tools for laboratory professionals.
Grifols’ primary focus is on the production of medicines derived from human plasma, a rich source of essential proteins. Patients throughout Canada and around the world rely on our plasma medicines to treat rare and life-threatening conditions such as immune deficiencies, hemophilia, and genetic emphysema.
At Grifols, we take pride in our innovative achievements, strong customer service, sterling safety record and adherence to the highest standards of honesty and professional ethics. We have an unwavering commitment to the development of safer and more effective blood and plasma therapies as well as innovative products designed for hospitals, laboratory professionals and healthcare providers.
About Grifols Canada
On June 1, 2011 Grifols inherited the 23-year legacy established in Canada by our predecessors, Talecris Biotherapeutics and Bayer Biological Products. As the primary supplier of plasma therapies to the Canadian blood system, Grifols is committed to maintaining the delivery of premier products and services that our Canadian patient communities have trusted for years. We will continue to strengthen and grow our valued relationships with our partners, including Canadian Blood Services, Héma-Québec, healthcare professionals, and patients. In fact, our team at Grifols Canada is largely composed of the same talented professionals you know and trust, and who understand your needs and the needs of the Canadian marketplace.
Grifols offers a portfolio of innovative protein therapies, and complementary programs and services in Canada. Our products include Gamunex®, IGIVnex®, Prolastin®-C, Plasbumin®, HyperTET®, GamaSTAN®, HyperRAB® and HyperHEP B®.